Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Terrosa

- PMLiVE

Sanofi and GSK share positive data for two COVID-19 booster vaccine trials

Both the COVIBOOST and phase 3 VAT02 trials showed the booster was well-tolerated, with favourable safety profiles

- PMLiVE

Sanofi and GSK share positive data for two COVID-19 booster vaccine trials

Both the COVIBOOST and phase 3 VAT02 trials showed the booster was well-tolerated, with favourable safety profiles

- PMLiVE

Sanofi and Regeneron receives FDA priority review for prurigo nodularis

Dupixent would be the first drug specifically indicated for the condition in the US

- PMLiVE

Sandoz launches ‘Act4Biosimilars’ initiative to address global health inequalities

The initiative wants to increase the global use of biosimilars by at least 30% by 2030

- PMLiVE

NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC

Eligible patients will now be able to access the treatment through the NHS in England

- PMLiVE

Eli Lilly announces $2.1bn investment in new manufacturing sites

The new sites will create around 500 jobs within the company

- PMLiVE

Sanofi and Regeneron receive FDA approval for eosinophilic oesophagitis treatment

Dupixent is the first and only drug specifically recommended for EoE in the US

- PMLiVE

Eli Lilly and Incyte’s Olumiant approved by FDA for hospitalised COVID-19 patients

Nearly one million people with COVID-19 have been treated with Olumiant in approximately 15 countries worldwide

- PMLiVE

Sanofi launches new funding foundation

Foundation S is a philanthropic endowment fund aimed at encouraging healthier lives for future generations

- PMLiVE

Sanofi and McLaren Racing come together to maximise performance and operational excellence

The partnership will complement Sanofi’s R&D pipeline, which has 25 new launches planned over the next five years

- PMLiVE

Sanofi’s Rezurock results show positive patient outcomes

Pooled analysis of chronic graft-versus-host disease treatment demonstrates organ clinical responses correlated with meaningful changes

- PMLiVE

Sanofi begins construction on the first of two Evolutive Vaccine Facilities in Singapore

The two sites aim to improve pandemic preparedness and will have an estimated cost of $1.3bn over the next five years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links